KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Interest Expenses for 13 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 8.17% to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.1 million, a 0.17% change, with the full-year FY2025 number at $18.1 million, changed 0.17% from a year prior.
  • Interest Expenses was $4.9 million for Q4 2025 at Halozyme Therapeutics, up from $4.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $7.5 million in Q3 2022 to a low of $1.8 million in Q2 2021.
  • A 5-year average of $4.0 million and a median of $4.5 million in 2023 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: crashed 64.99% in 2021, then surged 328.39% in 2022.
  • Halozyme Therapeutics' Interest Expenses stood at $2.1 million in 2021, then skyrocketed by 122.38% to $4.6 million in 2022, then increased by 14.22% to $5.2 million in 2023, then fell by 13.03% to $4.5 million in 2024, then grew by 8.17% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Interest Expenses are $4.9 million (Q4 2025), $4.3 million (Q3 2025), and $4.4 million (Q2 2025).